证券代码：603939 证券简称：益丰药房 公告编号：2023-064 益丰大药房连锁股份有限公司 重要内容提示： ● 限制性股票回购数量与价格： 关于第二次回购注销 2022 年限制性股票激励计划部 分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 回购数量：92,960 股，回购价格：17.58 元/股； 益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）于 2023 年 8 月 14 日召开的第四届董事会第二十九次会议与第四届监事会第二十四次会议 审议通过了《关于第二次回购注销 2022 年限制性股票激励计划部分限制性股票 的议案》。根据公司《2022 年限制性股票激励计划（修订版）》相关规定，对公司 限制性股票激励计划部分激励对象已获授但尚未解锁的限制性股票进行回购注 销。现将相关事项公告如下： 一、2022 年限制性股票激励计划回购注销审批程序及实施情况 1、2022 年 8 月 19 日，公司召开的第四届董事会第十六次会议与第四届监 事会第十四次会议，审议通过了《关于公司<2022 ...

湖南启元律师事务所 关于益丰大药房连锁股份有限公司 2022年限制性股票激励计划回购注销部分限 制性股票的 法律意见书 二〇二三年八月 致：益丰大药房连锁股份有限公司 湖南启元律师事务所（以下简称"本所"）受益丰大药房连锁股份有限公司 （以下简称"益丰药房"或"公司"）委托，担任公司实施 2022 年限制性股票激 励计划项目专项法律顾问，根据《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《益丰大药房连锁股份有限公司章程》（以下简称"《公司章程》"）、 《益丰大药房连锁股份有限公司 2022 年限制性股票激励计划（修订版）》（以下 简称"《激励计划》"）等有关规定，就公司回购注销部分 2022 年限制性股票（以 下简称"本次回购注销"）相关事项出具本法律意见书。 查，发表了核查意见。 2、2022 年 9 月 5 日，公司召开的 2022 年第三次临时股东大会审议通过了《关 于公司<2022 年限制性股票激励计划（草案）>及摘要的议案》《关于公司<2022 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请公司股东大 会授权董事会办理限制性股票激励计划相关事宜的议案》。并披露了《关于 2 ...

证券代码：603939 证券简称：益丰药房 公告编号：2023-063 益丰大药房连锁股份有限公司 第四届监事会第二十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 全体监事均亲自出席本次监事会。 无监事对本次监事会议案投反对/弃权票。 本次监事会全部议案均获通过。 本次会议由监事会主席陈斌先生召集并主持，采用记名投票方式，通过了如 下议案： 1. 审议通过了《关于第二次回购注销 2022 年限制性股票激励计划部分限制 性股票的议案》 鉴于公司 2022 年股权激励计划部分激励对象降职或离职原因，根据《上市 公司股权激励管理办法》、公司《2022 年限制性股票激励计划（修订版）》以及 《2022 年限制性股票激励计划实施考核管理办法》的有关规定，公司拟对其持 有的限制性股票合计 92,960 股股份进行回购注销。 监事会认为：公司本次回购注销限制性股票符合《上市公司股权激励管理办 法》及公司《2022 年限制性股票激励计划（修订版）》等相关规定，符合相关法 律、法规的规定，不存在损害公司 ...

证券代码：603939 证券简称：益丰药房 公告编号：2023-065 益丰大药房连锁股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原因 益丰大药房连锁股份有限公司（以下简称"公司"）于 2023 年 8 月 14 日召 开的第四届董事会第二十九次会议与第四届监事会第二十四次会议，审议通过 了《关于第二次回购注销 2022 年限制性股票激励计划部分限制性股票的议案》。 根据公司《2022 年限制性股票激励计划（修订版）》之"第十三章公司/激励对 象发生异动的处理"之"激励对象个人情况发生变化的处理"的规定，鉴于部分激 励对象离职或降级，公司将回购注销其已获授但尚未解除限售的部分限制性股 票，合计 92,960 股。具体内容详见公司同日披露的《关于第二次回购注销 2022 年限制性股票激励计划部分限制性股票的公告》。回购完毕后，公司将向中国 证券登记结算有限责任公司上海分公司申请注销该部分股票，注销完成后，公 司注册资本将因此减少 92960 元。 ...

证券代码：603939 证券简称：益丰药房 公告编号：2023-062 益丰大药房连锁股份有限公司 第四届董事会第二十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次董事会全部议案均获通过。 二、董事会会议审议情况 本次会议由董事长高毅先生召集并主持，采用记名投票方式，审议并通过了 如下议案： 1. 审议通过了《关于第二次回购注销 2022 年限制性股票激励计划部分限制 性股票的议案》 鉴于公司 2022 年股权激励计划部分激励对象降职或离职的原因，根据《上 市公司股权激励管理办法》、公司《2022 年限制性股票激励计划（修订版）》以 及《2022 年限制性股票激励计划实施考核管理办法》的有关规定，公司拟对其 持有的限制性股票合计 92,960 股股份进行回购注销。 表决情况为：9 票同意，0 票反对，0 票弃权。 一、董事会会议召开情况 益丰大药房连锁股份有限公司（以下简称"公司"）于 2023 年 8 月 10 日以电 子邮件方式发出第四届董事会第二十九次会议通知，会议于 202 ...

证券代码：603939 证券简称：益丰药房 公告编号：2023-043 益丰大药房连锁股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 26 日(星期五)下午 15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频和网络互动 投资者可于 2023 年 05 月 18 日(星期四)至 05 月 25 日(星期四)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@yfdyf.com 进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 益丰大药房连锁股份有限公司（以下简称"公司"）将于 2023 年 4 月 28 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 05 月 26 ...

Financial Performance - The company achieved a net profit attributable to the parent company of CNY 1,265,609,879.99 in 2022, with a total distributable profit of CNY 3,720,020,128.04 at year-end[4]. - The company's operating revenue for 2022 was approximately ¥19.89 billion, representing a year-over-year increase of 29.75% compared to ¥15.33 billion in 2021[18]. - Net profit attributable to shareholders for 2022 was approximately ¥1.27 billion, a 42.54% increase from ¥887.88 million in 2021[19]. - The net profit after deducting non-recurring gains and losses was approximately ¥1.23 billion, reflecting a 43.27% increase from ¥858.72 million in 2021[19]. - The company generated a net cash flow from operating activities of approximately ¥3.92 billion, an increase of 82.34% compared to ¥2.15 billion in 2021[19]. - Basic earnings per share for 2022 were ¥1.76, a 40.80% increase from ¥1.25 in 2021[20]. - The weighted average return on equity increased to 15.82%, up 2.79 percentage points from 13.03% in 2021[20]. - The company's total assets reached approximately ¥21.04 billion, a 23.38% increase from ¥17.05 billion in 2021[19]. - The gross profit margin for the main business was 38.27%, a decrease of 0.19 percentage points compared to the previous year, primarily due to an increase in wholesale revenue proportion[59]. Store Expansion and Operations - The total number of stores increased by 2,459 to a total of 10,268 stores by the end of the reporting period, including 1,962 franchise stores[21]. - The company opened 2,816 new stores during the reporting period, including 1,241 self-built stores and 545 acquired stores[21]. - The company operates 10,268 retail pharmacies across ten provinces and municipalities, with a net increase of 2,459 stores during the reporting period, resulting in a year-on-year revenue growth of 29.75% and a net profit increase of 42.54%[48]. - The company has established seven modern logistics centers in Hunan, Hubei, Jiangsu, Shanghai, Jiangxi, Guangdong, and Hebei, enhancing its digital supply chain capabilities with advanced equipment and technology[46]. - The company has achieved a compound annual growth rate of 37.90% in store numbers from 2017 to 2022, demonstrating its effective chain replication and industry consolidation capabilities[49]. Risk Management and Compliance - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[5]. - The company has maintained a standard unqualified audit opinion from Tianjian Accounting Firm[3]. - The board of directors and management have confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company has not violated decision-making procedures for external guarantees[5]. - The report includes a detailed description of potential risks in the "Management Discussion and Analysis" section[6]. Research and Development - The company invested CNY 25,309,639.00 in R&D, marking a 61.80% increase from the previous year[56]. - R&D expenses totaled ¥35,475,108.04, with capitalized R&D accounting for 56.09% of total R&D investment[67]. - The company has a total of 342 R&D personnel, making up 0.95% of the total workforce[68]. Corporate Governance - The company has established a performance evaluation system and transparent incentive mechanisms for its board members and senior management[110]. - The company held its first extraordinary general meeting on April 18, 2022, with 22 shareholders present, representing 66.78% of the voting rights, and approved one resolution regarding changes to the business scope and amendments to the Articles of Association[116]. - The company has conducted seven shareholder meetings during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[108]. Shareholder Engagement and Dividends - A cash dividend of CNY 4.00 per 10 shares (including tax) is proposed, with an expected total cash dividend distribution of CNY 288,681,972.00[4]. - The total cash dividend amount for 2022 is projected to be 288,681,972.00 RMB, which represents 22.81% of the net profit attributable to ordinary shareholders in the consolidated financial statements[147]. - The company has not made any adjustments to its cash dividend policy during the reporting period, adhering strictly to its established profit distribution policies[142]. Market Trends and Industry Insights - The Chinese pharmaceutical market is projected to grow from approximately $170 billion in 2021 to over $200 billion by 2026, indicating significant industry expansion potential[36]. - The retail pharmacy market in China reached sales of 542.1 billion yuan in 2022, reflecting a year-on-year increase of 10.2%, marking the best growth rate in five years[42]. - The integration of "Internet + healthcare" is driving the development of the pharmaceutical industry, with ongoing reforms enhancing market dynamics[36]. Digital Transformation and Innovation - The company has implemented a comprehensive digital transformation, enhancing operational efficiency and customer experience through data-driven strategies[32]. - The company is focused on digital transformation, aiming to create a digital high-efficiency service system to improve operational efficiency and reduce fulfillment costs[101]. - The company has integrated e-commerce into its retail strategy since 2013, evolving into a new retail model that combines online and offline services[47]. Environmental and Social Responsibility - The company invested 0 million yuan in environmental protection during the reporting period[155]. - The company promotes "green office" practices, with over 30,000 users in its collaborative office management system, significantly reducing paper usage[157]. - Energy-saving measures are strictly enforced, including controlling air conditioning usage and promoting water conservation[158].

Financial Performance - The company's operating revenue for Q1 2023 reached ¥5,266,053,201.98, representing a year-on-year increase of 26.94%[3] - The net profit attributable to shareholders was ¥336,477,177.44, reflecting a growth of 23.60% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥321,446,423.67, which is a 20.80% increase year-on-year[3] - The basic earnings per share for the period was ¥0.47, up by 23.68% from the previous year[3] - Total revenue for Q1 2023 reached ¥5,266,053,201.98, a 27.0% increase from ¥4,148,494,215.04 in Q1 2022[20] - Net profit for Q1 2023 was ¥379,869,656.04, representing a 25.8% increase compared to ¥301,846,217.02 in Q1 2022[22] - Total profit for Q1 2023 was ¥500,816,745.84, up from ¥407,279,978.80 in Q1 2022, indicating a 23.0% growth[22] - Comprehensive income total for Q1 2023 was ¥470,476,565.53, compared to ¥301,846,217.02 in Q1 2022, showing a 55.9% increase[22] Cash Flow - The net cash flow from operating activities was ¥1,288,846,164.43, showing a significant increase of 98.87%[3] - Cash flow from operating activities for Q1 2023 was ¥1,288,846,164.43, a significant increase from ¥648,087,580.21 in Q1 2022[23] - The net cash flow from investing activities was -$1,313,579,823.08, compared to -$545,566,623.69 in the previous year, indicating a significant increase in cash outflow for investments[24] - The total cash outflow from investing activities was $1,381,141,313.01, compared to $614,232,584.77 in the same period last year, reflecting a substantial increase[24] - The net cash flow from financing activities was -$341,525,797.58, slightly higher than -$338,683,047.06 in the previous year[24] - The net decrease in cash and cash equivalents was -$366,259,456.23, compared to -$236,162,090.54 in the previous year, indicating a worsening cash position[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥21,399,378,617.37, a 1.71% increase from the end of the previous year[4] - The total assets as of March 31, 2023, amounted to 21,399,378,617.37 RMB, an increase from 21,038,886,640.04 RMB at the end of 2022[16] - The total liabilities as of March 31, 2023, were 11,774,060,177.95 RMB, down from 11,917,419,653.19 RMB at the end of 2022[17] - The company's cash and cash equivalents decreased to 3,571,532,389.09 RMB from 4,112,519,204.66 RMB at the end of 2022, reflecting a decline of approximately 13.2%[15] - The company's accounts receivable decreased to 1,285,324,434.99 RMB from 1,843,940,879.13 RMB, a reduction of about 30.3%[15] - The company's equity attributable to shareholders increased to 9,013,837,501.90 RMB from 8,556,078,527.92 RMB, representing a growth of approximately 5.3%[17] Store Expansion and Mergers - In Q1 2023, the company added 661 new stores, including 308 self-built stores, 154 acquired stores, and 199 franchised stores, resulting in a total of 10,865 stores, a net increase of 597 stores compared to the previous period[10] - The company completed 4 mergers and acquisitions in the industry during the reporting period, with 3 projects finalized, including the acquisition of 100% equity of a new company for 113 million RMB involving 54 stores and 8 clinics[11] Research and Development - Research and development expenses for Q1 2023 were ¥4,637,452.27, slightly up from ¥4,174,752.27 in Q1 2022[20] Other Financial Metrics - Non-recurring gains and losses for the period totaled ¥15,030,753.77, after accounting for tax and minority interests[5] - The weighted average return on equity increased by 0.28 percentage points to 3.85%[3] - The company reported a total inventory of 3,488,889,401.55 RMB, a slight decrease from 3,614,549,276.03 RMB at the end of 2022[15] - The company’s long-term equity investments stood at 5,249,082.40 RMB, remaining stable compared to the previous period[16] - The company’s total non-current assets increased to 10,942,725,254.65 RMB from 10,460,663,228.00 RMB, indicating a growth of approximately 4.6%[16] - Other comprehensive income after tax for Q1 2023 was ¥90,606,909.49, with no previous year comparison available[22]